^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Small Intestinal Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    …the NCCN Panel recommends either pembrolizumab or nivolumab, with or without ipilimumab, as second-line treatment options for dMMR/MSI-H advanced SBA.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Colorectal Cancer)
    New
    Title:

    FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer

    Excerpt:
    The Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).